Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2)

Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) 是一种抗小鼠 Delta-like protein 4/DLL4 IgG 单克隆抗体,可通过阻断 DLL4-Notch 信号通路减少血管生成和密度,通过降低 NF-κB 活性和促炎因子 (IL-1β、iNOS、IL-6) 水平减少炎症反应,抑制 Th17 细胞分化和 IL-17A 的产生,并减少巨噬细胞浸润、缓解胰岛素抵抗,可用于研究炎症、代谢疾病和癌症,如动脉粥样硬化、胰腺癌和哮喘。
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2)
产品编号: MS-Q59006 分子量: 150 kDa
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
询价
5mg
询价
询价
10mg
询价
询价

产品描述

Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) 是一种抗小鼠 Delta-like protein 4/DLL4 IgG 单克隆抗体,可通过阻断 DLL4-Notch 信号通路减少血管生成和密度,通过降低 NF-κB 活性和促炎因子 (IL-1β、iNOS、IL-6) 水平减少炎症反应,抑制 Th17 细胞分化和 IL-17A 的产生,并减少巨噬细胞浸润、缓解胰岛素抵抗,可用于研究炎症、代谢疾病和癌症,如动脉粥样硬化、胰腺癌和哮喘。

生物实验数据

生物活性 Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) is an anti-mouse Delta-like protein 4/DLL4 IgG monoclonal antibody that reduces angiogenesis and vascular density by blocking the DLL4-Notch signaling pathway, decreases inflammatory responses by lowering NF-κB activity and the levels of pro-inflammatory factors (IL-1β, iNOS, IL-6), inhibits Th17 cell differentiation and IL-17A production, and reduces macrophage infiltration and alleviates insulin resistance, making it suitable for research on inflammation, metabolic diseases, and cancers such as atherosclerosis, pancreatic cancer, and asthma.
IC50 & Target

NF-κB

 

iNOS

 

FGFR1

 

IL-6

 

IL-1β

 

IL-17A

 

体内研究
(In Vivo)

Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) (12.5 µg/kg,腹腔注射,每 2 天或每 3 天一次,持续 15 天) 在亚致死性照射下改变 Balb/c 小鼠的骨髓血管结构,促进骨髓分化。
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) (250 μg,腹腔注射,每周两次,持续 5 周) 显著抑制携带 PK-1 肿瘤的雄性 SCID 小鼠的肿瘤生长。
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) (250 μg,腹腔注射,每周两次,持续 12 周) 显著改善了高脂肪和高胆固醇饮食的 Ldlr-/- 小鼠和 Lepob/Lepob 小鼠的动脉粥样硬化、胰岛素抵抗、肥胖和其他代谢异常。
Anti-Mouse Delta-like protein 4/DLL4 Antibody (HMD4-2) (250 μg,腹腔注射,在第 15、18 和 21 天) 改善了 Toluene diisocyanate (TDI) 诱导的哮喘模型雌性 BALB/c 小鼠的气道炎症和哮喘症状。

Animal Model: Balb/c mice with a sub-lethally irradiation (6-8 weeks)
Dosage: 12.5 µg/kg
Administration: Intraperitoneal injection (i.p.), once every 2 days or every 3 days, for 15 days
Result: Increased CD31+, VE Cadherin+ and c-kit+ vascular density.
Increased megakaryocytes (CD41+) and myeloid cells (CD11b+).
Reduced B (B220+) and T (CD3+) lymphocytes.
Upregulated the mRNA levels of IGFbp2/3, Angpt2, DLL4, DHH, and VEGF-A.
Downregulated the levels of FGF1 and CSF2.
Animal Model: 1×107 PK-1 cells injected male SCID mice (6-8 weeks)
Dosage: 250 μg
Administration: Intraperitoneal injection (i.p.), twice a week, for 5 weeks
Result: Significantly inhibited tumor volume.
Significantly reduced the generation and density of blood vessels.
Did not cause significant toxicity or tissue damage.
Animal Model: Ldlr-/- mice and Lepob/Lepob mice with a high fat and high cholesterol diet (8 weeks)
Dosage: 250 μg
Administration: Intraperitoneal injection (i.p.), twice a week, for 12 weeks
Result: Reduced plaque area and MCP-1 and macrophage infiltration.
Increased collagen and reduced calcification.
Reduced fat weight and made fat cells smaller.
Reduced fasting insulin levels.
Decreased NF-κB activity and expression of pro-inflammatory cytokines (IL-1β, iNOS, IL-6).
Animal Model: TDI (0.3% ear application and 3% nebulized inhalation) induced female BALB/c mice (6-8 weeks)
Dosage: 250 μg
Administration: Intraperitoneal injection (i.p.), on day 15, 18 and 21
Result: Significantly reduced airway hyperreactivity (AHR) and airway inflammation score.
Significantly improved epithelial damage.
Significantly reduced the total number of inflammatory cells in bronchoalveolar lavage fluid (BALF), collagen deposition and airway smooth muscle (α-SMA).
Significant decreased in the proportion of Th17 and Th1 cells.
Significant decreased in IL-17A and RORγt levels.

化学信息

分子量 150 kDa

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础